An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

NCT02038673 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
86
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Astellas Pharma Inc

Collaborators